Monster Beverage: Momentum Brewing, But Shares Are Fairly Priced

Assorted Monster Energy drink cans showcasing product variety, highlighting Monster Beverage (MNST) growth in the energy drink market.

Excerpt

The following is a 250-word excerpt from my full article on Seeking Alpha: A crowdsourced financial market content service where investors can share ideas, discuss news, and make informed investment decisions. To view the full article without a paywall, please click on the link below:

https://seekingalpha.com/article/4820666?gt=f5cdb280b6c9863b

Summary

  • I give Monster Beverage Corporation a hold rating.

  • The company has a solid balance sheet, with an equity to debt ratio of 82-18 and enough cash on hand to pay off all liabilities.

  • Monster Beverage's Peter Lynch earnings line indicates the stock's value to be at $59.43, meaning the stock is currently trading at around 11.36% above its earnings line.

  • Monster had record earnings for Q2, with excellent July sales and momentum for Q3; but the company did not purchase shares in Q2, meaning they are exercising caution for Q3.

  • The company has high quality earnings, and my discounted cash flow model indicates an intrinsic value of $64.38 per share, meaning the stock is trading 2.76% above its intrinsic value.

A Personal Anecdote

I've been wanting to do analysis on Monster for quite some time, mostly because I drink a lot of Monster Energy, specifically the original green version. I am quite the caffeine fiend, and the kick that I get after drinking 160mg worth of caffeine always hits the spot if I'm not in the mood for coffee. And I'll be honest: Until I opened up the company's latest 10-K, I had no idea that Monster had such a deep lineup of products. So, let's break down how the company makes their money…

Alexander I. Velasquez

Alexander I. Velasquez specializes in stock analysis, investing, and financial research. He delivers thoughtful, research-driven insights, and his work is published on Seeking Alpha.

https://seekingalpha.com/author/alexander-i-velasquez
Next
Next

Niagen Bioscience: A Great Company Suffering From Stock Dilution